Calidi Biotherapeutics Valuation

Is CLDI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CLDI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CLDI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CLDI's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CLDI?

Key metric: As CLDI is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CLDI. This is calculated by dividing CLDI's market cap by their current book value.
What is CLDI's PB Ratio?
PB Ratio	-4x
Book	-US$10.28m
Market Cap	US$37.28m

CLDI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-1.7x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does CLDI's PB Ratio compare to its peers?

The above table shows the PB ratio for CLDI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	1.8x
CVM CEL-SCI	4.4x	22.5%	US$37.9m
RGLS Regulus Therapeutics	1.2x	22.6%	US$100.2m
OVID Ovid Therapeutics	1x	-20.6%	US$77.4m
ABOS Acumen Pharmaceuticals	0.6x	-11.5%	US$132.2m
CLDI Calidi Biotherapeutics	n/a	-5.6%	US$37.3m

Price-To-Book vs Peers: CLDI has negative equity and a Price-To-Book Ratio (-4x) compared to the peer average (1.8x).

Price to Book Ratio vs Industry

How does CLDI's PB Ratio compare vs other companies in the US Biotechs Industry?

59 Companies	Price / Book	Estimated Growth	Market Cap
GRAL GRAIL	0.2x	35.7%	US$588.69m
AMRN Amarin	0.4x	-7.7%	US$205.50m
IMAB I-Mab	0.4x	1.8%	US$77.18m
MGX Metagenomi	0.3x	-23.2%	US$75.22m

59 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: CLDI has negative equity and a Price-To-Book Ratio (-4x) compared to the US Biotechs industry average (1.9x).

Price to Book Ratio vs Fair Ratio

What is CLDI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CLDI PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	-4x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CLDI's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CLDI forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	US$2.14	US$6.25 +192.1%	60.0%	US$10.00	US$2.50	n/a	2
Nov ’25	US$1.35	US$6.25 +363.0%	60.0%	US$10.00	US$2.50	n/a	2
Oct ’25	US$1.09	US$6.25 +473.4%	60.0%	US$10.00	US$2.50	n/a	2
Sep ’25	US$1.14	US$15.00 +1,215.8%	33.3%	US$20.00	US$10.00	n/a	2
Aug ’25	US$1.67	US$15.00 +798.2%	33.3%	US$20.00	US$10.00	n/a	2
Jul ’25	US$1.93	US$15.00 +677.2%	33.3%	US$20.00	US$10.00	n/a	2
May ’25	US$1.93	US$32.50 +1,583.9%	38.5%	US$45.00	US$20.00	n/a	2
Apr ’25	US$5.53	US$32.50 +487.7%	38.5%	US$45.00	US$20.00	n/a	2
Mar ’25	US$6.27	US$100.00 +1,494.1%	10.0%	US$110.00	US$90.00	n/a	2
Feb ’25	US$8.00	US$100.00 +1,150.0%	10.0%	US$110.00	US$90.00	n/a	2
Jan ’25	US$15.10	US$100.00 +562.3%	10.0%	US$110.00	US$90.00	n/a	2
Dec ’24	US$21.90	US$100.00 +356.6%	10.0%	US$110.00	US$90.00	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Collegium Pharmaceutical

US$1.0b

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.71

2.4%

20.0%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$59.39

7.8%

20.6%

IQVIA Holdings

US$36.5b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.43

3.6%

-5.8%